Pharmacological lipid modification therapy following stroke: an update

References

• Fonarow GC, Smith EE, Reeves MJ et al. Hospital‑level variation in mortality and rehospitalisation for Medicare beneficiaries with acute ischemic stroke. Stroke 42, 159–166 (2011).
   Google Scholar
• Royal College of Physicians National Sentinel Stroke Clinical Audit 2010 Round 7 Public report for England, Wales and Northern Ireland. Prepared on behalf of the Intercollegiate Stroke Working Party May 2011 P43.
   Google Scholar
• Adamson J, Beswick A, Shah E. Is stroke the most common cause of disability? J. Stroke Cerebrovasc. Dis. 13 (4), 171–177 (2004).
   Google Scholar
• Mohan KM, Wolfe CDA, Rudd AG et al. Risk and cumulative risk of stroke recurrence: a systemic review and meta analysis. Stroke 42(5), 1489–1494 (2011).
   Google Scholar
• Furie KL, Kasner SE, Adams RJ et al. Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42, 227–276 (2011). ▪▪ Comprehensive guidance from the American Heart Association/American Stroke Association covering all aspects of management of acute stroke.
   Google Scholar
• European Stroke Initiative recommendations for stroke management – update 2003. Cerebrovasc. Dis. 16, 311–337 (2003).
   Google Scholar
• Lewington S, Whitlock G, Clarke R et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370(9602), 1829–1839 (2007).
   Google Scholar
• Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta‑analysis of statins for stroke prevention. Lancet Neurol. 8(5), 453–463 (2009).
   Google Scholar
• Sett A, Robinson TG, Mistri AK. Current status of statin therapy for stroke prevention. Exp. Rev. Cardiovasc. Ther. 9(10), 1305–14 (2011).
   Google Scholar
• Lindenstrøm E, Boysen G, Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol and triglycerides on risk of cerebrovascular disease. BMJ 1994, 11–15 (1994).
   Google Scholar
• Iso H, Jacobs DR Jr, Wentworth D et al. Serum cholesterol levels and six‑year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial (MRFIT). N. Engl. J. Med. 320(14), 904–910 (1989).
   Google Scholar
• Imamura T, Doi Y, Arima H et al. LDL cholesterol and the development of stroke subtypes and coronary heart disease in a general Japanese population: the Hisayama study. Stroke 40(2), 382–388 (2009).
   Google Scholar
• Asia Pacific Cohort Studies Collaboration. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int. J. Epidemiol. 32, 563–572 (2003).
   Google Scholar
• Goldstein LB, Amarenco P, Szarek M et al. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Study. Neurology 70, 2364–2370 (2008).
   Google Scholar
• Vergouwen MD, de Haan RJ, Vermeulen M et al. Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease. Stroke 39, 497–502 (2008).
   Google Scholar
• Wang X, Dong Y, Qi X et al. Cholesterol Levels and risk of hemorrhagic stroke a systematic review and meta‑analysis. Stroke 44, 1833–1839 (2013).
   Google Scholar
• Labreuche J, Touboul PJ, Amarenco P. Plasma triglyceride levels and risk of stroke and carotid atherosclerosis: a systematic review of the epidemiological studies. Atherosclerosis 203(2), 331–345 (2009).
   Google Scholar
• Freiberg JJ, Tybjaerg‑Hansen A, Jensen JS et al. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 300(18), 2142–2152, (2008).
   Google Scholar
• Psaty BM, Anderson M, Kronmal RA et al. The association between lipid levels and the risk of incident myocardial infarction, stroke, and total mortality: the Cardiovascular Health Study. J. Am. Geriatr. Soc. 52(10), 1639–1647 (2004).
   Google Scholar
• Amarenco P, Labreuche J, Touboul PJ. Highdensity lipoprotein‑cholesterol and risk of stroke and carotid atherosclerosis: a systematic review. Atherosclerosis 196(2), 489–496 (2008).
   Google Scholar
• Amarenco P, Labreuche J, Lavallée P, Touboul PJ. Statin in stroke prevention and carotid atherosclerosis: systematic review and meta‑analysis. Stroke 35, 2902–2909 (2004).
   Google Scholar
• Mangravite LM, Wilke RA, Zhang J et al. Pharmacogenetics of statin response. Curr. Opin. Mol. Ther. 10 (6), 555–561 (2008).
   Google Scholar
• Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group. Effects of cholesterol‑lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease and other high risk conditions. Lancet 363, 757–767 (2004).
   Google Scholar
• Luvai A, Mbagaya W, Hall AS et al. Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease. Clin. Med. Insights Cardiol. 6, 17–33 (2012).
   Google Scholar
• Kishida K, Funahashi T, Shimomura I. Effect of pitavastatin on HDL metabolism. Clin. Lipidol. 8(1), 55–68 (2013).
   Google Scholar
• Zhou YH, Ye XF, Yu FF et al. Lipid management in the prevention of stroke: a meta‑analysis of fibrates for stroke prevention. BMC Neurol. 13(1)(2013).
   Google Scholar
• Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? ControlClin. Trials 17(1), 1–12 (1998).
   Google Scholar
• The Bezafibrate Infarction Prevention (BIP) study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patient with coronary artery disease: Circulation 102, 21–27 (2000).
   Google Scholar
• Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high‑density lipoprotein cholesterol. N. Engl. J. Med. 341, 410–418 (1999).
   Google Scholar
• Acheson J, Hutchinson EC. Controlled trial of clofibrate in cerebral vascular disease. Atherosclerosis 15, 177–183 (1972).
   Google Scholar
• The Veterans Administration Cooperative Study Group: The treatment of cerebrovascular disease with clofibrate. Final report of the Veterans Administration Cooperative Study of Atherosclerosis, Neurology Section. Stroke 4, 684–693(1973).
   Google Scholar
• The ACCORD Study Group. Effects of combination lipid therapy in Type 2 diabetes mellitus. NEJM 362, 1563–1574 (2010).
   Google Scholar
• Catapano A, Toth PP, Tomassini JE et al. The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups. Clin. Lipidol. 8(1), 13–41 (2013).
   Google Scholar
• Teo KK, Goldstein LB, Chaitman BR et al. Extended‑release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease. Stroke 44, 2688–2693 (2013).
   Google Scholar
• HPS2‑THRIVE Collaborative Group. HPS2‑THRIVE randomized placebocontrolled trial in 25 673 high‑risk patients of ER niacin/laropiprant: trial design, prespecified muscle and liver outcomes, and reasons for stopping study treatment. Eur. Heart J. 34(17), 1279–1291 (2013).
   Google Scholar
• Rizos EC, Ntzani EE, Bika E et al. Association between omega‑3 fatty acid supplementation and risk of major cardiovascular disease events – a systematic review and meta‑analysis. JAMA 308(10), 1024–1033 (2012).
   Google Scholar
• Blom DJ, Marais AD, Raal FJ et al. The potential use of monoclonal antibodies and other novel agents as drugs to lower LDL cholesterol. Clin. Lipidol. 8(2), 243–256 (2013). ▪ Good summary of upcoming interventions for the management of dyslipidemia.
   Google Scholar
• Flint AC, Kamel H, Navi BB et al. Statin use during ischemic stroke hospitalization is strongly associated with improved poststroke survival. Stroke 43, 147–154 (2012).
   Google Scholar
• Dowlatshahi D, Demchuk AM, Fang J et al. Registry of the Canadian Stroke Network. Association of statins and statin discontinuation with poor outcome and survival after intracerebral hemorrhage. Stroke 43, 518–1523 (2012).
   Google Scholar
• Blanco M, Nombella F, Castellanos M et al. statin treatment withdrawal in ischemic stroke – a controlled randomized study. Neurology 69, 904–910 (2007). ▪ Small randomized study of statin withdrawal that demonstrated significantly worse outcomes with discontinuation of prestroke statin therapy in acute stroke.
   Google Scholar
• Kennedy J, Hill MD, Ryckborst KJ et al. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol. 6(11), 9610969 (2007). ▪ Major study of early intervention with de novo statin therapy following ischemic stroke or transient ischemic attack, unfortunately closed early due to poor recruitment with no significant results to guide acute statin therapy.
   Google Scholar
• Squizzato A, Romualdi E, Dentali F et al. Statins for acute ischemic stroke. Cochrane Database Syst. Rev. 8, CD007551 (2011). ▪▪ Systematic review summarizing studies investigating statin therapy in the acute phase of ischemic stroke, underpinning current recommendations in international guidelines.
   Google Scholar
• Amarenco P, Bogousslavsky J, Callahan A 3rd et al.; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High‑dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med. 355, 549–559 (2006). ▪▪ Landmark study, and to this date, the only study that demonstrated significant benefit with statin therapy in patients with a history of stroke or transient ischemic attack. The conclusions have been adopted by all major guidelines and form the cornerstone of recommendations for statin therapy following stroke or transient ischemic attack.
   Google Scholar
• Colivicchi F, Bassi A, Santini M et al. Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke 38(10), 2652–2657 (2007). ▪ Key study highlighting poor compliance with statin therapy following acute stroke.
   Google Scholar
• Joubert J, Reid C, Barton D et al. Integrated care improves risk‑factor modification after stroke: initial results of the Integrated Care for the Reduction of Secondary Stroke model. J. Neurol. 80(3), 279–284 (2009). ▪▪ Important study suggesting potential beneficial effects on risk factor profile with the use of an integrated care pathway for stroke survivors.
   Google Scholar
• Adie K, James MA. Does telephone follow‑up improve blood pressure after minor stroke or TIA? Age Ageing 39(5), 598–603 (2010).
   Google Scholar